P
Paolo Lombardi
Researcher at University of Palermo
Publications - 85
Citations - 2435
Paolo Lombardi is an academic researcher from University of Palermo. The author has contributed to research in topics: Berberine & Pancreatic cancer. The author has an hindex of 23, co-authored 83 publications receiving 2074 citations. Previous affiliations of Paolo Lombardi include University of Southampton & University of Sassari.
Papers
More filters
Journal ArticleDOI
Berberine: new perspectives for old remedies.
TL;DR: A growing body of reports supports the evidence that berberine has anticancer effects, being able to block the proliferation of and to kill cancer cells.
Journal ArticleDOI
Berberine, an epiphany against cancer.
TL;DR: The results so far obtained on human cancer cell lines support the idea that alkaloids could be promising agents for cancer treatment, and the main properties of berberine and derivatives will be illustrated.
Journal ArticleDOI
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
James A. McCubrey,Kvin Lertpiriyapong,Linda S. Steelman,Steve L. Abrams,Li V. Yang,Ramiro Mendonça Murata,Pedro Luiz Rosalen,Aurora Scalisi,Luca M. Neri,Lucio Cocco,Stefano Ratti,Alberto M. Martelli,Piotr Laidler,Joanna Dulińska-Litewka,Dariusz Rakus,Agnieszka Gizak,Paolo Lombardi,Ferdinando Nicoletti,Saverio Candido,Massimo Libra,Giuseppe Montalto,Melchiorre Cervello +21 more
TL;DR: This review will focus on a few natural products, especially on resveratrol (RES), curcumin (CUR) and berberine (BBR), which have potent anti-cancer effects and may extend human lifespan by activating the sirtuins and SIRT1 molecules.
Journal ArticleDOI
6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A New Irreversible Aromatase Inhibitor
TL;DR: FCE 24304 (6-methylenandrosta-1,4-diene-3,17-dione), a new irreversible aromatase inhibitor, has been identified and characterized in vitro and in vivo and little binding affinity for the androgen receptor was observed.
Journal ArticleDOI
New developments in antitumor anthracyclines
Federico Arcamone,Fabio Animati,Giovanni Capranico,Paolo Lombardi,Graziella Pratesi,Stefano Manzini,Rosanna Supino,Franco Zunino +7 more
TL;DR: Doxorubicin is a major anticancer agent introduced to extended clinical use in the early 1970s and is presently undergoing clinical trials as a third generation antitumor anthracycline.